Connect Biopharma Holdings Limited
Science and Technology Park
East R&D Building, 3rd Floor
6 Beijing West Road, Taicang
Jiangsu Province, China 215400
March 16, 2021
VIA EDGAR
Ms. Ada D. Sarmento
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Connect Biopharma Holdings Limited |
| Registration Statement on Form F-1 |
| File No. 333-253631 |
Dear Ms. Sarmento:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited (the “Company”), respectfully requests that the effective date of the Registration Statement on Form F-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on March 18, 2021, or as soon as practicable thereafter.
Please contact Michael E. Sullivan of Latham & Watkins LLP, counsel to the Company, at (858) 523-3959, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
| Very truly yours, | ||
| CONNECT BIOPHARMA HOLDINGS LIMITED | ||
| By: | /s/ Zheng Wei, Ph.D. | |
| Zheng Wei, Ph.D. | ||
| Chief Executive Officer | ||
| cc: | Eric Atallah, Securities and Exchange Commission |
| Vanessa Robertson, Securities and Exchange Commission |
| Tim Buchmiller, Securities and Exchange Commission |
| Wubin Pan, Ph.D., Connect Biopharma Holdings Limited |
| Patrick A. Pohlen, Latham & Watkins LLP |
| Michael E. Sullivan, Latham & Watkins LLP |
| Jeffrey T. Woodley, Latham & Watkins LLP |